NASDAQ: SHOTSafety Shot Inc Stock
$4.76-0.84 (-15%)
Updated Dec 5, 2023
SHOT Price
$4.76
Fair Value Price
$4.91
Market Cap
$189.53M
52 Week Low
$0.31
52 Week High
$7.50
P/E
-6.7x
P/B
28.25x
P/S
9.15x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.88M
Earnings
-$17.94M
Gross Margin
16.4%
Operating Margin
-359.94%
Profit Margin
-367.8%
Debt to Equity
0.69
Operating Cash Flow
-$7M
Beta
0.7
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SHOT Overview
Jupiter Wellness, Inc. develops cannabidiol (CBD) based medical therapeutics and wellness products. It also manufactures consumer products such as CBD-infused sunscreen under the CaniSun brand, CBD-infused skin care lotion under the CaniSkin brand, and products for dermatological treatment of pain and inflammation under the CaniDermRX brand. Jupiter Wellness was incorporated in 2018 and is headquartered in Jupiter, FL.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SHOT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SHOT ($4.76) is undervalued by 2.98% relative to our estimate of its Fair Value price of $4.91 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SHOT ($4.76) is not significantly undervalued (2.98%) relative to our estimate of its Fair Value price of $4.91 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SHOT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SHOT due diligence checks available for Premium users.
Be the first to know about important SHOT news, forecast changes, insider trades & much more!
SHOT News
Valuation
SHOT fair value
Fair Value of SHOT stock based on Discounted Cash Flow (DCF)
Price
$4.76
Fair Value
$4.91
Undervalued by
2.98%
SHOT ($4.76) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SHOT ($4.76) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SHOT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SHOT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.7x
Industry
15.83x
Market
30.4x
SHOT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
28.25x
Industry
2.02x
SHOT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SHOT's financial health
Profit margin
Revenue
$484.2k
Net Income
-$7.7M
Profit Margin
-1,598.2%
SHOT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SHOT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$11.3M
Liabilities
$4.6M
Debt to equity
0.69
SHOT's short-term assets ($8.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SHOT's short-term assets ($8.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SHOT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.9M
Investing
-$2.1M
Financing
$6.7M
SHOT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SHOT vs Pharmaceutical Stocks
Safety Shot Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.